Arbutus Biopharma Corp Unbilled Receivables, Current
Arbutus Biopharma Corp (ABUS) had Unbilled Receivables, Current of $0 as of 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:UnbilledReceivablesCurrent · last filed 2019-03-07
- 2013-12-31: Unbilled Receivables, Current 212.38K CAD.
- 2012-12-31: Unbilled Receivables, Current 2.37M CAD; Unbilled Receivables, Current as first filed 2.36M CAD.
- 2011-12-31: Unbilled Receivables, Current 185.36K CAD.
- 2010-12-31: Unbilled Receivables, Current 817.46K CAD.
CAD
| Period end | Unbilled Receivables, Current | Unbilled Receivables, Current as first filed |
|---|---|---|
| 2013-12-31 | 212.38K CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 2.37M CAD 10-K · filed 2014-03-28 | 2.36M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 185.36K CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 817.46K CAD 20-F · filed 2012-03-27 |
USD
| Period end | Unbilled Receivables, Current |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-07 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-03 |
| 2018-03-31 | $128.00K 10-Q · filed 2018-05-04 |
| 2017-12-31 | $128.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $128.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $128.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $128.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $128.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $128.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $128.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $128.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $128.00K 10-K · filed 2017-03-22 |
| 2015-09-30 | $454.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $323.00K 10-Q · filed 2015-08-07 |
| 2015-03-31 | $1.59M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $538.00K 10-K · filed 2016-03-09 |
| 2014-09-30 | $152.00K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $200.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $412.00K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $212.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |